Pershing Square (PS) has an average rating of hold and mean price target of $40, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Price: $36.50, Change: $+0.83, Percent Change: +2.33%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We maintain a 12-month target of $50, based on a FY 27 (Jul.) P/E of 28.6x, a justified discount to CPRT's five-year average forward P/E of 32.4x. We lower our adjusted EPS estimates to $1.60 from $1.65 for FY 26 and to $1.75 from $1.80 for FY 27. Following a much better-than-expected earnings release from CPRT, we are lowering our estimates but maintaining a Strong Buy and $50 price target. In our view, the biggest positive was CPRT's aggressive buyback activity ($1.41B of stock repurchased in the Apr-Q, a sharp increase from $218M in the prior two quarters) and the fact that both segments posted top-line growth following a quarter in which both service and vehicle sales were lower on a Y/Y basis. The share count reduction should help fuel stronger EPS going forward and set the stage for stronger bottom-line results. Importantly, CPRT's balance sheet still possesses $4.1B of net cash, and we think aggressive buybacks are likely to continue in the near-term. Meanwhile, fundamental headwinds appear to be easing.
CIBC Capital Markets lowered its price target on CAE Inc. (CAE.TO) to $44 from $56.Analyst Krista Friesen maintained an Outperformer rating on shares of the Canadian manufacturer of simulation technologies, modelling technologies and training services to airlines, aircraft manufacturers, and defence customers."There has been significant anticipation around the long-term targets from CAE's new management team, and with those now established, the focus has shifted to execution," Friesen said in a note to clients.
AlphaValue/Baader Europe on Tuesday downgraded biopharmaceutical group Sartorius Stedim Biotech (DIM.PA) to add from buy and kept the price target at 217.00 euros.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)